carvedilol has been researched along with Coronary Heart Disease in 39 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized, double-blind study oral doses of 50 mg carvedilol (Dilatrend) were compared with 40 mg propranolol in 16 male patients with coronary heart disease, CHD [12 without significant stenoses following percutaneous transluminal coronary angioplasty (PTCA), 4 with multivessel disease]." | 9.07 | Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease. ( Wendt, T, 1992) |
| "Carvedilol is a novel, multiple-action cardiovascular drug that is currently approved in many countries for the treatment of hypertension." | 8.79 | Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1997) |
| "Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)." | 7.71 | Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002) |
| "Carvedilol is a new drug which possesses a balanced combination of vasodilatation and beta-blockade." | 6.67 | The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. ( Broadhurst, P; DasGupta, P; Lahiri, A, 1991) |
| " Exercise testing, radionuclide ventriculography, and right-sided cardiac catheterization were performed and intraarterial blood pressure measured before and after 8 weeks of carvedilol therapy in a dosage of 12." | 5.28 | Value of carvedilol in congestive heart failure secondary to coronary artery disease. ( Broadhurst, P; Das Gupta, P; Lahiri, A; Raftery, EB, 1990) |
| "In a randomized, double-blind study oral doses of 50 mg carvedilol (Dilatrend) were compared with 40 mg propranolol in 16 male patients with coronary heart disease, CHD [12 without significant stenoses following percutaneous transluminal coronary angioplasty (PTCA), 4 with multivessel disease]." | 5.07 | Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease. ( Wendt, T, 1992) |
| "In a randomized double-blind study, oral doses of 50 mg carvedilol were compared to 40 mg propranolol in 16 male patients with coronary heart disease (12 without significant stenosis after percutaneous transluminal coronary angioplasty) at rest, during and after exercise, and before and 80 min after drug application." | 5.06 | Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol. ( Kober, G; Landgraf, H; Schräder, R; van der Does, R; Wendt, T, 1987) |
| "Carvedilol is a novel, multiple-action cardiovascular drug that is currently approved in many countries for the treatment of hypertension." | 4.79 | Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1997) |
| "Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)." | 3.71 | Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002) |
| "Carvedilol is a direct inhibitor of vascular smooth muscle cell migration and proliferation through inhibition of mitogen-activated protein kinase activity and regulation of cell cycle progression." | 2.71 | Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting. ( Cha, KS; Kim, DI; Kim, DS; Kim, HJ; Kim, JS; Kim, JW; Kim, MH, 2004) |
| "Carvedilol is a novel beta-blocker that also shows an antioxidant effect in vitro." | 2.69 | Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. ( Akita, H; Kanazawa, K; Matsuda, Y; Shiga, N; Terashima, M; Yokoyama, M, 2000) |
| "Carvedilol is a multiple-action cardiovascular agent that is both a beta-adrenoceptor antagonist and a vasodilator and has recently been made available for the treatment of mild-to-moderate hypertension." | 2.67 | Myocardial protection with carvedilol. ( Bril, A; Feuerstein, GZ; Hamburger, SA; Ruffolo, RR; Smith, EF, 1992) |
| "Carvedilol is a new drug which possesses a balanced combination of vasodilatation and beta-blockade." | 2.67 | The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. ( Broadhurst, P; DasGupta, P; Lahiri, A, 1991) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| "The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy)." | 2.41 | [Prevention and treatment of congestive heart failure in diabetic patients]. ( Anguita Sánchez, M, 2002) |
| "Carvedilol is a dual-acting drug designed to produce two complementary effects: beta-blockade and vasodilation." | 2.38 | Vasodilatory action of carvedilol. ( Bartsch, W; Müller-Beckmann, B; Sponer, G; Strein, K, 1992) |
| "Carvedilol is a third-generation vasodilating beta-adrenoceptor antagonist with advantageous ancillary pharmacologic properties for the treatment of the patient with high blood pressure complicated by CAD." | 2.38 | Hypertension and coronary artery disease: a therapeutic challenge. ( Taylor, SH, 1991) |
| "Both propranolol and verapamil were slightly more active than carvedilol in inhibiting epinephrine-induced platelet aggregation, a trend consistent with the IC50 values." | 1.28 | Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers. ( Betterridge, DJ; Gasser, JA, 1991) |
| " Exercise testing, radionuclide ventriculography, and right-sided cardiac catheterization were performed and intraarterial blood pressure measured before and after 8 weeks of carvedilol therapy in a dosage of 12." | 1.28 | Value of carvedilol in congestive heart failure secondary to coronary artery disease. ( Broadhurst, P; Das Gupta, P; Lahiri, A; Raftery, EB, 1990) |
| "carvedilol was studied during repeated 2-min distal LAD-occlusions and a 60-min-period of ischemia." | 1.28 | Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs. ( Ehmer, B; Friedrich, M; Hirche, H; Höher, M; Hombach, V; Marten, A; Sommer, T, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (12.82) | 18.7374 |
| 1990's | 21 (53.85) | 18.2507 |
| 2000's | 12 (30.77) | 29.6817 |
| 2010's | 1 (2.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guzeloglu, M | 1 |
| Ertuna, E | 1 |
| Arun, MZ | 1 |
| Reel, B | 1 |
| Besler, C | 1 |
| Doerries, C | 1 |
| Giannotti, G | 1 |
| Lüscher, TF | 1 |
| Landmesser, U | 1 |
| Anguita Sánchez, M | 1 |
| Cohen-Solal, A | 1 |
| Logeart, D | 1 |
| Guiti, C | 1 |
| Bourgoin, P | 1 |
| Callaerts-Vegh, Z | 1 |
| Evans, KL | 1 |
| Shipley, GL | 1 |
| Davies, PJ | 1 |
| Cuba, DL | 1 |
| Gurji, HA | 1 |
| Giles, H | 1 |
| Bond, RA | 1 |
| Patel, MR | 1 |
| Gattis, W | 1 |
| Cha, KS | 1 |
| Kim, MH | 1 |
| Kim, JW | 1 |
| Kim, DI | 1 |
| Kim, HJ | 1 |
| Kim, DS | 1 |
| Kim, JS | 1 |
| Bell, DS | 1 |
| Krauser, DG | 1 |
| Devereux, RB | 1 |
| Fox, K | 1 |
| Borer, JS | 1 |
| Camm, AJ | 1 |
| Danchin, N | 1 |
| Ferrari, R | 1 |
| Lopez Sendon, JL | 1 |
| Steg, PG | 1 |
| Tardif, JC | 1 |
| Tavazzi, L | 1 |
| Tendera, M | 1 |
| Zehender, M | 1 |
| Just, H | 1 |
| Ruffolo, RR | 2 |
| Feuerstein, GZ | 2 |
| Landray, MJ | 1 |
| Kendall, MJ | 1 |
| Parker, JD | 1 |
| Schwartz, RS | 1 |
| Lubbe, D | 1 |
| Altman, J | 1 |
| Holmes, DR | 1 |
| Serruys, PW | 1 |
| Foley, DP | 1 |
| Höfling, B | 1 |
| Puel, J | 1 |
| Glogar, HD | 1 |
| Seabra-Gomes, R | 1 |
| Goicolea, J | 1 |
| Coste, P | 1 |
| Rutsch, W | 1 |
| Katus, H | 1 |
| Bonnier, H | 1 |
| Wijns, W | 1 |
| Betriu, A | 1 |
| Hauf-Zachariou, U | 1 |
| van Swijndregt, EM | 1 |
| Melkert, R | 1 |
| Simon, R | 1 |
| Matsuda, Y | 1 |
| Akita, H | 1 |
| Terashima, M | 1 |
| Shiga, N | 1 |
| Kanazawa, K | 1 |
| Yokoyama, M | 1 |
| Kulbertus, H | 1 |
| Yaoita, H | 1 |
| Sakabe, A | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| DasGupta, P | 4 |
| Lahiri, A | 5 |
| Wendt, T | 2 |
| Hamburger, SA | 1 |
| Smith, EF | 1 |
| Bril, A | 1 |
| Sponer, G | 2 |
| Strein, K | 2 |
| Bartsch, W | 1 |
| Müller-Beckmann, B | 1 |
| Sievert, H | 2 |
| Schmidt, T | 2 |
| Frey, G | 2 |
| Schräder, R | 3 |
| van der Does, R | 5 |
| Kaltenbach, M | 2 |
| Kober, G | 3 |
| Broadhurst, P | 2 |
| Hashimoto, H | 1 |
| Kanda, A | 1 |
| Hubo, H | 1 |
| Tanaka, M | 1 |
| Gasser, JA | 1 |
| Betterridge, DJ | 1 |
| Taylor, SH | 1 |
| Buchwald, A | 1 |
| Unterberg, C | 1 |
| Wiegand, V | 1 |
| Das Gupta, P | 1 |
| Raftery, EB | 2 |
| Prichard, BN | 1 |
| Kaski, JC | 1 |
| Rodriguez-Plaza, L | 1 |
| Brown, J | 1 |
| Maseri, A | 1 |
| Landgraf, H | 1 |
| Rodrigues, EA | 1 |
| Jain, D | 1 |
| Höher, M | 1 |
| Friedrich, M | 1 |
| Sommer, T | 1 |
| Marten, A | 1 |
| Ehmer, B | 1 |
| Hombach, V | 1 |
| Hirche, H | 1 |
| Mauser, M | 1 |
| Voelker, W | 1 |
| Ickrath, O | 1 |
| Hoffmeister, HM | 1 |
| Karsch, KR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI[NCT02351674] | 15,000 participants (Anticipated) | Observational | 2015-01-31 | Not yet recruiting | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for carvedilol and Coronary Heart Disease
| Article | Year |
|---|---|
Pharmacological approaches to improve endothelial repair mechanisms.
Topics: AC133 Antigen; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2008 |
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin | 2002 |
Advantages of a third-generation beta-blocker in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Coronary Disease; Diabetes Complications; Human | 2004 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
[Value of beta-blocker therapy in treatment of coronary heart disease and sudden cardiac death with special reference to carvedilol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Coronary Disease; Death, Sudden | 1996 |
Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Arteriosclerosis; Carbazoles; Cardiov | 1997 |
Coronary artery disease and antioxidants--is there a role for carvedilol?
Topics: Carbazoles; Carvedilol; Coronary Disease; Free Radical Scavengers; Humans; Lipid Peroxidation; Lipop | 1997 |
Local arterial drug delivery: a golden gun without bullets?
Topics: Carbazoles; Carvedilol; Catheterization; Coronary Disease; Drug Delivery Systems; Humans; Injections | 1999 |
Vasodilatory action of carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilo | 1992 |
Hypertension and coronary artery disease: a therapeutic challenge.
Topics: Animals; Blood Pressure; Carbazoles; Carvedilol; Coronary Disease; Humans; Hypertension; Propanolami | 1991 |
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Celiprolol; Coronary Disease; Heart Fa | 1990 |
Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Disease; Hemodynamics; Humans | 1990 |
13 trials available for carvedilol and Coronary Heart Disease
| Article | Year |
|---|---|
Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Atenolol; C | 2004 |
Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial.
Topics: Adrenergic Antagonists; Aged; Antioxidants; Atherectomy, Coronary; Carbazoles; Carvedilol; Coronary | 2000 |
Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Antioxidants; Carbazoles; Carvedilol; Case-Control Studies; Coronary Di | 2000 |
Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Carbazo | 1992 |
Myocardial protection with carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Disease; Dogs; Heart; Injecti | 1992 |
Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; | 1992 |
[Neither propranolol nor the vasodilating beta-blocker carvedilol have a direct effect on coronary resistance vessels].
Topics: Adrenergic beta-Antagonists; Blood Flow Velocity; Blood Pressure; Carbazoles; Carvedilol; Coronary A | 1991 |
The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Coronary Disease; Female; Heart Failure; | 1991 |
[Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Coronary Disease; Doub | 1990 |
Influence of carvedilol and propranolol on coronary blood flow.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Coronary Circulation; Coronary | 1990 |
Efficacy of carvedilol in exercise-induced myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Blood Pressure; Carbazoles; Carvedilol; C | 1987 |
Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Coronary Disease; Double | 1987 |
[The acute hemodynamic effects of the new vasodilating beta blocker carvedilol in comparison with combined administration of nifedipine and propranolol in patients with coronary heart disease].
Topics: Carbazoles; Carvedilol; Coronary Circulation; Coronary Disease; Drug Therapy, Combination; Female; H | 1989 |
13 other studies available for carvedilol and Coronary Heart Disease
| Article | Year |
|---|---|
Effects of carvedilol on vascular reactivity in human left internal mammary artery.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Coronary Artery Bypass; Coronary Disease; | 2017 |
[Use of carvedilol in daily practice].
Topics: Adrenergic beta-Antagonists; Bradycardia; Carbazoles; Cardiology; Carvedilol; Coronary Disease; Drug | 1999 |
Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Carbazoles; Carvedilol; Coronary Disease; Coronary | 2003 |
Which beta-blocker for heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Coronary Disease | 2004 |
To trust or not to trust.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coron | 1999 |
[Info-congress. COPERNICUS and Val-HEFT studies].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coron | 2000 |
Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Ascorbic Acid; Carbazoles; Cardi | 2002 |
Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Carbazoles; Carved | 1992 |
Features of the acute hypotensive action of carvedilol and its ameliorating effect on myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Coronary Disease; Dogs | 1991 |
Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers.
Topics: Adrenergic beta-Antagonists; Blood Platelets; Carbazoles; Carvedilol; Coronary Disease; Cyclic AMP; | 1991 |
Value of carvedilol in congestive heart failure secondary to coronary artery disease.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Catheterization; Carved | 1990 |
Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Carbazoles; Carvedilol; Coronary Disease; Exercise Tes | 1989 |
Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Carbazoles; Cardiography, Impedance; C | 1989 |